A new study found that approximately one-third of men with prostate cancer were diagnosed with at least one vertebral fracture prior to the initiation of androgen deprivation therapy (ADT).
Based on findings from a new study, researchers are advocating for systematic risk assessment of vertebral fractures in all patients who about to commence with androgen deprivation therapy (ADT) for prostate cancer (PCa).
In a cross-sectional study of 115 men (mean age of 73.3 years) with PCa, researchers assessed 10-year fracture risk, bone mineral density (via dual-energy X-ray absorptiometry) and possible vertebral fractures (via lateral X-rays of the thoracic and lumbar spine) prior to patients beginning androgen deprivation therapy (ADT). The study authors noted that 90 men (78.3 percent) in the cohort had localized PCa and 25 men (21.7 percent) had advanced PCa.
Researchers found low 10-year risks for hip fracture (1.7 percent) and osteoporotic fracture (4.4 percent), and a low rate of osteoporosis (4.3 percent as per bone mineral density testing), according to the study, which was recently published in the Journal of Bone Oncology. However, the authors also found that 32.2 percent of the study cohort had at least one vertebral fracture and spinal X-rays revealed osteoporosis and/or a vertebral fracture in 33.9 percent of the study participants.
“Vertebral fragility fractures are often asymptomatic and overlooked but are known to decrease quality of life, and can also affect mortality,” wrote study co-author Caroline E. Wyers, PhD, who is affiliated with the Department of Internal Medicine at the VieCuri Medical Centre in Venlo, the Netherlands, and colleagues. “These findings underline the importance of systematic imaging of the spine to detect prevalent (vertebral fractures) in PCa patients at initiation of ADT, improving identification of true incident (vertebral fractures) during ADT.”
(Editor’s note: For related content, see “Key Highlights from the Annual Symposium of the American Society of Spine Radiology” and “Could an Emerging PSMA/PET Imaging Agent Improve the Detection of Recurrent Prostate Cancer?”)
Wyers and colleagues noted that the most common locations for vertebral fractures were in the mid-thoracic (Th7-Th8) and thoracolumbar (Th12) areas of the spine. The study authors added that the majority of moderate and severe vertebral fractures occurred among men who had normal bone mineral density as well as study participants who had osteopenia.
In regard to study limitations, the study authors acknowledged that the cross-sectional study did not allow for assessment of direct correlations between risk factors and incident fractures. Wyers and colleagues noted the potential of selection bias as multiple factors, including physician and patient preferences, contribute to a decision to utilize ADT treatment. The researchers also pointed out that the predominantly Caucasian study cohort may prohibit broad extrapolation of the study findings.
Study Shows MRI-Targeted Biopsies Reduce Overdiagnosis of Clinically Insignificant PCa by 57 Percent
September 27th 2024Omitting biopsy procedures in men with PSA levels > 3 ng/ml and negative MRI findings for prostate cancer (PCa) was associated with significantly lower risks of diagnosing clinically insignificant PCa in comparison to the use of systematic biopsy, according to an approximately four-year study of over 13,000 men who had prostate cancer screening.
PSMA PET/CT or mpMRI: Which is Better for Diagnosing Biochemical Recurrence of PCa?
September 24th 2024A new meta-analysis found that PSMA PET/CT offers a 12 percent higher positivity rate for detecting biochemical recurrence of PCa and a 19 percent higher positivity rate for identifying lymph node metastasis in comparison to mpMRI.
Emerging PSMA Radioligand Therapy Shows Benefits for Metastatic Castration-Resistant Prostate Cancer
September 16th 2024The PSMA-targeted modality 177Lu-PNT2002 improved radiographic progression-free survival by 29 percent in patients with mCRPC in comparison to ARPI therapy, according to new phase 3 trial data presented at the ESMO Congress in Spain.